Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TMT2005-13R - Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 [anti-CD45 monoclonal antibody] in Patients With Advanced Leukemia.

Next Previous
Trial Profile

TMT2005-13R - Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 [anti-CD45 monoclonal antibody] in Patients With Advanced Leukemia.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD45 monoclonal antibody Y-90 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 29 Nov 2017 Biomarkers information updated
  • 14 May 2010 Planned end date changed from 1 Jul 2008 to 1 Dec 2007 as reported by ClinicalTrials.gov.
  • 14 May 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top